Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H18N6O3.2ClH |
| Molecular Weight | 463.317 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=CC=C(C=C1OC)C2=CC3=NC=CN3C(NC4=NC=CC=C4C(N)=O)=N2
InChI
InChIKey=SPMFEULFGGPQLN-UHFFFAOYSA-N
InChI=1S/C20H18N6O3.2ClH/c1-28-15-6-5-12(10-16(15)29-2)14-11-17-22-8-9-26(17)20(24-14)25-19-13(18(21)27)4-3-7-23-19;;/h3-11H,1-2H3,(H2,21,27)(H,23,24,25);2*1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H18N6O3 |
| Molecular Weight | 390.3953 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26930276 | https://www.ncbi.nlm.nih.gov/pubmed/22815993 | https://www.ncbi.nlm.nih.gov/pubmed/26720004 | https://www.ncbi.nlm.nih.gov/pubmed/24828076 | https://www.ncbi.nlm.nih.gov/pubmed/21730355
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26930276 | https://www.ncbi.nlm.nih.gov/pubmed/22815993 | https://www.ncbi.nlm.nih.gov/pubmed/26720004 | https://www.ncbi.nlm.nih.gov/pubmed/24828076 | https://www.ncbi.nlm.nih.gov/pubmed/21730355
BAY 61-3606 is a potent inhibitor of spleen tyrosine kinase (Syk) which is playing essential roles in receptors for Fc portion of immunoglobulins and B cell receptor complex signaling in various inflammatory cells. In addition, BAY61-3606 could inhibit the inhibitor of nuclear factor kappa B kinase (IKK-alpha) kinase activity. The compound is able to inhibit neoplastic phenotype of leukemia cells as well as of colon and breast cancer cells in vitro. BAY 61-3606 also exrets antiinflammatory and antiallergic properties in animal models.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2599 |
7.5 nM [Ki] | ||
Target ID: CHEMBL3476 |
45.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. | 2003 Sep |
|
| BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro. | 2012 |
|
| Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia. | 2014 May 14 |
|
| Inhibition of IKKα by BAY61-3606 Reveals IKKα-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells. | 2016 |
|
| Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling. | 2017 Jul |
Patents
Sample Use Guides
Oral administration of BAY 61-3606 to rats significantly suppressed antigen-induced passive cutaneous anaphylactic reaction, bronchoconstriction, and bronchial edema at 3 mg/kg.
Route of Administration:
Oral
BAY 61-3606 inhibited not only degranulation (IC50 values between 5 and 46 nM) but also lipid mediator and cytokine synthesis in mast cells. BAY 61-3606 was highly efficacious in basophils obtained from healthy human subjects (IC50 = 10 nM) and seems to be at least as potent in basophils obtained from atopic (high serum IgE) subjects (IC50 = 8.1 nM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:44:18 GMT 2023
by
admin
on
Sat Dec 16 09:44:18 GMT 2023
|
| Record UNII |
96PPV9GQ7A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20215179
Created by
admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
|
PRIMARY | |||
|
648903-57-5
Created by
admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
|
PRIMARY | |||
|
11784504
Created by
admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
|
PRIMARY | |||
|
96PPV9GQ7A
Created by
admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
